NL8803126A - Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten. - Google Patents

Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten. Download PDF

Info

Publication number: NL8803126A
Authority: NL; Netherlands
Prior art keywords: compound; cyclodextrin; hydrochloride; solution; water
Prior art date: 1987-12-22

Application number

NL8803126A

Other languages

English (en)

Dutch (nl)

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-22

Filing date

1988-12-21

Publication date

1989-07-17

1987-12-22 Priority claimed from GB878729823A external-priority patent/GB8729823D0/en

1988-02-25 Priority claimed from GB888804422A external-priority patent/GB8804422D0/en

1988-12-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1989-07-17 Publication of NL8803126A publication Critical patent/NL8803126A/nl

Links

238000002360 preparation method Methods 0.000 title claims description 33
-1 PIPERIDINYL CYCLOPENTYL Chemical class 0.000 title claims description 8
239000002253 acid Substances 0.000 title 1
229920000858 Cyclodextrin Polymers 0.000 claims description 74
229940126062 Compound A Drugs 0.000 claims description 66
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 66
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 41
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
238000002347 injection Methods 0.000 claims description 29
239000007924 injection Substances 0.000 claims description 29
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 29
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 24
229960004853 betadex Drugs 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 24
239000001116 FEMA 4028 Substances 0.000 claims description 20
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 20
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 11
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 10
229940080345 gamma-cyclodextrin Drugs 0.000 claims description 10
239000012458 free base Substances 0.000 claims description 5
238000001802 infusion Methods 0.000 claims description 5
229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 4
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 4
229940043377 alpha-cyclodextrin Drugs 0.000 claims description 4
239000004615 ingredient Substances 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
239000000243 solution Substances 0.000 description 54
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 9
229930195725 Mannitol Natural products 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
239000000594 mannitol Substances 0.000 description 9
235000010355 mannitol Nutrition 0.000 description 9
229940097362 cyclodextrins Drugs 0.000 description 8
239000002585 base Substances 0.000 description 7
239000008363 phosphate buffer Substances 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 6
238000007911 parenteral administration Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000003814 drug Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000012265 solid product Substances 0.000 description 4
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
229910000397 disodium phosphate Inorganic materials 0.000 description 3
235000019800 disodium phosphate Nutrition 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
235000019980 sodium acid phosphate Nutrition 0.000 description 3
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000007429 general method Methods 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000008055 phosphate buffer solution Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
JAIYKLJZOBJGSG-UHFFFAOYSA-N 2-cyclopentyl-3-piperidin-1-ylhept-2-enoic acid Chemical class C1CCCC1C(C(O)=O)=C(CCCC)N1CCCCC1 JAIYKLJZOBJGSG-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
206010050902 Postoperative thrombosis Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
201000002676 cerebral atherosclerosis Diseases 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
CJCPHVRHJKYIJC-UHFFFAOYSA-N methyl 2-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=CC=C1O CJCPHVRHJKYIJC-UHFFFAOYSA-N 0.000 description 1
239000003595 mist Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
JWYIRZRIDBKTPH-UHFFFAOYSA-N propyl 2-hydroxybenzoate;sodium Chemical compound [Na].CCCOC(=O)C1=CC=CC=C1O JWYIRZRIDBKTPH-UHFFFAOYSA-N 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nanotechnology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

NL8803126A 1987-12-22 1988-12-21 Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten. NL8803126A (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8729823		1987-12-22
GB878729823A GB8729823D0 (en)	1987-12-22	1987-12-22	Complexes
GB888804422A GB8804422D0 (en)	1988-02-25	1988-02-25	Complexes
GB8804422		1988-02-25

Publications (1)

Publication Number	Publication Date
NL8803126A true NL8803126A (nl)	1989-07-17

Family

ID=26293226

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8803126A NL8803126A (nl)	1987-12-22	1988-12-21	Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten.

Country Status (29)

Country	Link
JP (1)	JPH02210A (de)
KR (1)	KR890009402A (de)
CN (1)	CN1034132A (de)
AT (1)	AT395943B (de)
AU (1)	AU615245B2 (de)
BE (1)	BE1001704A3 (de)
CA (1)	CA1328078C (de)
CH (1)	CH676665A5 (de)
DE (1)	DE3843059A1 (de)
DK (1)	DK712888A (de)
ES (1)	ES2011727A6 (de)
FI (1)	FI885920A (de)
FR (1)	FR2624731B1 (de)
GB (1)	GB2211737B (de)
GR (1)	GR880100854A (de)
HU (1)	HU204700B (de)
IE (1)	IE61995B1 (de)
IL (1)	IL88764A0 (de)
IT (1)	IT1224835B (de)
LU (1)	LU87411A1 (de)
MY (1)	MY103952A (de)
NL (1)	NL8803126A (de)
NO (1)	NO885689L (de)
NZ (1)	NZ227446A (de)
PH (1)	PH24982A (de)
PL (1)	PL276595A1 (de)
PT (1)	PT89301B (de)
SE (1)	SE502288C2 (de)
ZW (1)	ZW18088A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8814725D0 (en) *	1988-06-21	1988-07-27	Glaxo Group Ltd	Medicaments
AU616571B2 (en) *	1988-10-28	1991-10-31	Shiseido Company Ltd.	Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
IT1269578B (it) *	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
KR100825736B1 (ko) *	2005-12-07	2008-04-29	한국전자통신연구원	무선 ｘｍｌ 전자 서명 서비스 제공 장치 및 그 방법
KR100832740B1 (ko) *	2007-01-17	2008-05-27	한국과학기술원	분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS503362B1 (de) *	1970-06-10	1975-02-04
JPS5443569B2 (de) *	1972-07-05	1979-12-20
HU181703B (en) *	1980-05-09	1983-11-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS57183772A (en) *	1981-04-29	1982-11-12	Glaxo Group Ltd	Aminocyclopentanol acids and esters, manufacture and medicinal composition
JPS58116423A (ja) *	1981-12-28	1983-07-11	Sumitomo Chem Co Ltd	メタノプロスタサイクリン製剤組成物
JPS58192821A (ja) *	1982-04-30	1983-11-10	Dainippon Pharmaceut Co Ltd	脳神経細胞の酸素欠乏性疾患の治療剤
JPS5946228A (ja) *	1982-09-08	1984-03-15	Zeria Shinyaku Kogyo Kk	生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
JPS5973576A (ja) *	1982-09-16	1984-04-25	グラクソ・グル−プ・リミテツド	ピペリジニルシクロペンタノ−ルヘプテン酸塩
GB2127406B (en) *	1982-09-16	1986-03-05	Glaxo Group Ltd	Piperidinlycyclopentanolheptenoic acid salt
DE3346123A1 (de) *	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60150039A (ja) *	1984-01-17	1985-08-07	Minolta Camera Co Ltd	水陸両用固定焦点カメラ
DE3504044A1 (de) *	1985-02-04	1986-08-07	Schering AG, Berlin und Bergkamen, 1000 Berlin	9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
JPS6327440A (ja) *	1986-07-18	1988-02-05	Sanraku Inc	グルコシル化分岐シクロデキストリン含有組成物

1988
- 1988-12-21 HU HU886537A patent/HU204700B/hu not_active IP Right Cessation
- 1988-12-21 LU LU87411A patent/LU87411A1/fr unknown
- 1988-12-21 JP JP63320759A patent/JPH02210A/ja active Pending
- 1988-12-21 DK DK712888A patent/DK712888A/da not_active Application Discontinuation
- 1988-12-21 AU AU27356/88A patent/AU615245B2/en not_active Ceased
- 1988-12-21 BE BE8801423A patent/BE1001704A3/fr not_active IP Right Cessation
- 1988-12-21 AT AT0313088A patent/AT395943B/de not_active IP Right Cessation
- 1988-12-21 ZW ZW180/88A patent/ZW18088A1/xx unknown
- 1988-12-21 DE DE3843059A patent/DE3843059A1/de not_active Ceased
- 1988-12-21 FI FI885920A patent/FI885920A/fi not_active Application Discontinuation
- 1988-12-21 PT PT89301A patent/PT89301B/pt not_active IP Right Cessation
- 1988-12-21 PH PH37963A patent/PH24982A/en unknown
- 1988-12-21 GB GB8829793A patent/GB2211737B/en not_active Expired - Fee Related
- 1988-12-21 GR GR880100854A patent/GR880100854A/el unknown
- 1988-12-21 CH CH4758/88A patent/CH676665A5/de not_active IP Right Cessation
- 1988-12-21 NZ NZ227446A patent/NZ227446A/xx unknown
- 1988-12-21 CN CN88108916A patent/CN1034132A/zh active Pending
- 1988-12-21 ES ES8803876A patent/ES2011727A6/es not_active Expired - Fee Related
- 1988-12-21 NO NO88885689A patent/NO885689L/no unknown
- 1988-12-21 FR FR8816902A patent/FR2624731B1/fr not_active Expired - Fee Related
- 1988-12-21 PL PL27659588A patent/PL276595A1/xx unknown
- 1988-12-21 IE IE382088A patent/IE61995B1/en not_active IP Right Cessation
- 1988-12-21 KR KR1019880017106A patent/KR890009402A/ko not_active Application Discontinuation
- 1988-12-21 CA CA000586606A patent/CA1328078C/en not_active Expired - Fee Related
- 1988-12-21 IT IT8848702A patent/IT1224835B/it active
- 1988-12-21 SE SE8804607A patent/SE502288C2/sv not_active IP Right Cessation
- 1988-12-21 NL NL8803126A patent/NL8803126A/nl not_active Application Discontinuation
- 1988-12-22 MY MYPI88001508A patent/MY103952A/en unknown
- 1988-12-22 IL IL88764A patent/IL88764A0/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ227446A (en)	1991-08-27
SE502288C2 (sv)	1995-09-25
SE8804607D0 (sv)	1988-12-21
AT395943B (de)	1993-04-26
SE8804607L (sv)	1989-06-23
ES2011727A6 (es)	1990-02-01
FR2624731A1 (fr)	1989-06-23
GB8829793D0 (en)	1989-02-15
IL88764A0 (en)	1989-07-31
PL276595A1 (en)	1989-08-21
LU87411A1 (fr)	1989-07-07
BE1001704A3 (fr)	1990-02-13
IT1224835B (it)	1990-10-24
IE61995B1 (en)	1994-12-14
GB2211737B (en)	1991-12-11
AU2735688A (en)	1989-06-22
FR2624731B1 (fr)	1992-10-23
ZW18088A1 (en)	1989-07-26
FI885920A (fi)	1989-06-23
CA1328078C (en)	1994-03-29
IE883820L (en)	1989-06-22
PH24982A (en)	1990-12-26
DK712888D0 (da)	1988-12-21
NO885689L (no)	1989-06-23
HU204700B (en)	1992-02-28
NO885689D0 (no)	1988-12-21
PT89301A (pt)	1990-06-29
GB2211737A (en)	1989-07-12
JPH02210A (ja)	1990-01-05
KR890009402A (ko)	1989-08-01
ATA313088A (de)	1992-09-15
MY103952A (en)	1993-10-30
AU615245B2 (en)	1991-09-26
CH676665A5 (de)	1991-02-28
DK712888A (da)	1989-06-23
CN1034132A (zh)	1989-07-26
PT89301B (pt)	1995-07-03
HUT50040A (en)	1989-12-28
GR880100854A (el)	1994-03-31
IT8848702A0 (it)	1988-12-21
DE3843059A1 (de)	1989-07-13

Publication	Publication Date	Title
KR100983376B1 (ko)	2010-09-20	우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물의 제조방법
CA2414064C (en)	2013-01-08	Clear aqueous anaesthetic composition
CZ289746B6 (cs)	2002-03-13	Ve vodě rozpustná sůl nimesulidu, způsob její přípravy, vodný roztok, jenľ ji obsahuje, kombinace zaloľené na nimesulidu a jejich pouľití
EP2150245A1 (de)	2010-02-10	Verbindungen und verfahren zur erhöhung der löslichkeit von florfenicol und strukturell verwandten antibiotika mit cyclodextrinen
US4036954A (en)	1977-07-19	Stable prostaglandin E group-containing formulation
WO2001041757A1 (fr)	2001-06-14	Composition pharmaceutique contenant de la cyclodextrine
NL8803126A (nl)	1989-07-17	Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten.
JPS61286325A (ja)	1986-12-16	後天的免疫不全症の治療剤
US7259153B2 (en)	2007-08-21	Drug formulation and delivery using crystalline methylated cyclodextrins
JPH08500330A (ja)	1996-01-16	３−ジアルキルアミノエトキシベンゾイル−ベンゾフランを含有する非経口溶液
NL8102362A (nl)	1981-12-16	Farmaceutische antitumor-preparaat; werkwijze voor de bereiding daarvan.
FI90824B (fi)	1993-12-31	Menetelmä kylmäkuivattujen farmaseuttisten fenyylikinoliinikarboksyylihappokoostumusten valmistamiseksi
US5221695A (en)	1993-06-22	Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
IE51568B1 (en)	1987-01-21	Vincamine saccharinate and pharmaceutical compositions containing same
EP0348150A2 (de)	1989-12-27	Verwendung eines Thromboxan-Rezeptor-Antagonisten bei Krankheiten und Dysfunktionen der Niere
NL8101987A (nl)	1981-11-16	De verbinding 4-amino-1-beta-d-ribofuranosyl-1h-imidazo/4.5-c/-pyridine of een farmaceutisch aanvaardbaar zuuradditiezout daarvan; farmaceutisch preparaat.
WO1996041646A2 (en)	1996-12-27	Pharmaceutical compositions containing lornoxicam and cyclodextrin
CA2486571C (en)	2010-04-27	Pharmaceutical composition
EP0055593B1 (de)	1984-08-29	Präparate, die E-Prostaglandine enthalten
JPH0343251B2 (de)	1991-07-01
JPS61171421A (ja)	1986-08-02	安定なプロスタグランジンｅ類製剤の製造方法
RU2135474C1 (ru)	1999-08-27	Соли 1-дезокси-1-n-метиламиногексаспиртов с n-акридонуксусной кислотой, обладающие иммуномодулирующей активностью, и лекарственное средство на их основе
US4322424A (en)	1982-03-30	Crystalline glucoconate salt of m-AMSA and compositions containing same
US4575509A (en)	1986-03-11	Water-soluble formulations of m-AMSA with pyroglutamic acid
KR20240121186A (ko)	2024-08-08	주사용 조성물, 이를 포함하는 약학적 제제 및 이의 제조 방법

Legal Events

Date	Code	Title
1996-06-03	BA	A request for search or an international-type search has been filed
1996-08-01	BB	A search report has been drawn up
1997-02-03	BV	The patent application has lapsed